Single arm, open label, signal seeking, phase IIa trial of the activity of Durvalumab (MEDI4736) in combination with Tremelimumab in patients with advanced rare or neglected cancers.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Acronyms MoST addendum 2
- 07 Mar 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 12 Jun 2017 New trial record
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.